GIC, a sovereign wealth fund, agreed to acquire a minority stake in Grifols-backed Biomat USA, a health care company, for $1bn. Grifols will maintain control over Biomat’s management and operations, and all plasma collected by Biomat will continue to be supplied to Grifols to produce its plasma-derived medicines. “We are pleased to welcome GIC as a strategic investor to bolster and expand our US plasma center network, which is a clear competitive advantage. This transaction supports Grifols’ business model and our strategy in plasma collection, together with a solid innovation portfolio focused on disease management beyond the therapies based on plasma-derived medicines. With robust demand for Grifols’ plasma proteins, our efforts remain centered on doing our best to respond to the needs of patients and healthcare professionals," Víctor Grífols Deu, Grifols Co-CEO.